# Diabetes Research Hub — Monitor Report
**Date:** 2026-04-16
**Previous report:** 2026-04-15
**Data sources:** hub_monitor.py, clinical_trials_latest.json, pubmed_recent_latest.json, literature_gap_data.json, web search

---

## File System Status

All five key data files are present and current:

| File | Last Modified | Size | Status |
|------|-------------|------|--------|
| hub_monitor_report.md | 2026-04-16 07:05 | 4.8 KB | Fresh |
| clinical_trials_latest.json | 2026-04-16 07:05 | 514.3 KB | Fresh |
| pubmed_recent_latest.json | 2026-04-16 07:05 | 97.4 KB | Fresh |
| literature_gap_data.json | 2026-04-14 14:26 | 131.8 KB | 2 days old |
| literature_gap_report.md | 2026-04-15 13:50 | 11.7 KB | 1 day old |

**Hub-wide:** 708 files tracked. 3 new files, 28 modified files, 0 removed since last scan. The hub_monitor.py flagged 452 result files older than 14 days — many of these are historical snapshots and paper library entries, which is expected.

**New files today:**
- clinical_trials_snapshot_2026-04-16.json (514.3 KB)
- monitor_report_2026-04-15.md (7.1 KB)
- pubmed_recent_snapshot_2026-04-16.json (97.4 KB)

---

## Clinical Trial Changes

**Overview:** 765 total trials tracked across 5 categories. 262 recruiting, 259 completed, 130 not yet recruiting, 109 active (not recruiting).

### Snapshot Diff (Apr 15 → Apr 16)
- **New trials: 3** (all completed — newly indexed on ClinicalTrials.gov, not new enrollments)
- **Status changes: 0**
- **Removed trials: 0**

New trials added (all COMPLETED):
1. **NCT00690326** — Behavioral Change Communication for Physical Activity Among Females With T2D (Thiruvananthapuram Medical College)
2. **NCT05727579** — Dietary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, Renal Oxygenation (Amsterdam UMC, Phase 4)
3. **NCT06206525** — Feasibility Trial Using an Inpatient Insulin Dosing Calculator (University of Washington)

### Key Phase 3 Recruiting Trials (44 total)

**Highest-priority trials from key organizations:**

| NCT ID | Trial | Sponsor | Status |
|--------|-------|---------|--------|
| NCT06832410 | VX-880 Efficacy/Safety/Tolerability in T1D | Vertex Pharmaceuticals | RECRUITING Phase 3 |
| NCT04786262 | VX-880 Safety/Tolerability/Efficacy in T1D | Vertex Pharmaceuticals | RECRUITING Phase 3 |
| NCT07222137 | Baricitinib to Delay Stage 3 T1D in Adults | Eli Lilly | RECRUITING Phase 3 |
| NCT07222332 | Baricitinib to Preserve Beta Cell Function in Children/Adolescents | Eli Lilly | RECRUITING Phase 3 |
| NCT07076199 | Insulin Icodec (Weekly Insulin) in Reducing HbA1c | Novo Nordisk | RECRUITING Phase 3 |
| NCT07088068 | Teplizumab vs Placebo (new study) | Sanofi | RECRUITING Phase 3 |

**Other notable recruiting Phase 3 trials:**
- NCT06951074 — Insulin Producing Stem Cell Transplantation in T1D (Ain Shams University)
- NCT05819138 — Semaglutide Cardiovascular Outcomes in T1D (University of Colorado)
- NCT06217302 — Sotagliflozin to Slow Kidney Decline in T1D (Alessandro Doria)
- NCT06082063 — Multifactorial CV Risk Reduction in T1D (Steno Diabetes Center Copenhagen)
- NCT07258394 — Dimethyl Fumarate for Preserving Islet β-Cell Function in T1D (Nanjing Medical University)

**Key trials in ACTIVE_NOT_RECRUITING (results expected):**
- NCT06914895 — Tirzepatide vs Placebo in Adults With T1D (Eli Lilly, Phase 3)
- NCT06962280 — Long-Term Tirzepatide in T1D With Overweight (Eli Lilly, Phase 3)
- NCT05929079 — Retatrutide in T2D (Eli Lilly, Phase 3)
- NCT05791201 — VX-264 (Encapsulated Islets) in T1D (Vertex, Phase 1/2)
- NCT07271251 — Oral Semaglutide Formulation Comparison (Novo Nordisk, Phase 3)
- NCT06797869 — CagriSema Effects Study (Novo Nordisk, Phase 2)

**Results posted:** 260 trials in the tracker have posted results. No new results posted since yesterday's snapshot.

---

## PubMed Highlights

**Overview:** 127 unique papers across 15 alert domains in the last 30 days. 28 new papers and 28 dropped papers in today's snapshot vs. yesterday.

### Cross-Domain Papers (9 total — highest priority)

These papers appear in multiple alert domains and represent cross-disciplinary work:

1. **[41889910]** "Donor-derived CD8..." — Domains: T1D Stem Cell Cure, T1D Immunotherapy
   *Relevant to our Tier 3 monitoring areas (Stem Cell/Islet Biology + Immunology)*

2. **[41986815]** "Multi-tissue multi-omics integration reveals tissue-specific pathways, gene networks and drug candidates..." — Domains: Diabetes Drug Repurpose, Diabetes Multi-Omics
   *Directly relevant to Tier 1 areas: Multi-Omics Biomarker Integration AND Drug Repurposing*

3. **[41985330]** "Multi-strain probiotic enhances metformin tolerance by modulating gut microbiome and bile acid pathways" — Domains: Diabetes Microbiome, Diabetes Multi-Omics
   *Relevant to Tier 2: Microbiome-Metabolic Pathway Analysis*

4. **[41982769]** "Dietary fiber supplementation mitigates gestational diabetes risk and preterm birth via gut microbiota" — Domains: Diabetes Biomarker, Diabetes Microbiome

5. **[41980480]** "Blood-based biomarker discovery for early pregnancy loss using integrative multi-omics" — Domains: Diabetes Biomarker, Diabetes Multi-Omics

6. **[41982276]** "Association Between the Lactate-to-Albumin Ratio and ICU/In-Hospital Mortality in Critically Ill Patients" — Domains: Diabetes AI/ML, Diabetes Biomarker

7. **[41983640]** "Diagnosis of Mucormycosis: Current Situation, Challenges and Future Prospects" — Domains: Diabetes AI/ML, Diabetes Biomarker

8. **[41978270]** "Characterization of NLRP3 Inflammasome-Associated Hub Genes in the Progression of Diabetic..." — Domains: Diabetes Biomarker, Diabetes Complications New

9. **[41980294]** "Glucose metabolism's impact on Blastocystis presence in the human gut" — Domains: T2D Remission, Diabetes Microbiome

### Domain Volume (papers per domain, 30-day window)

Most domains returned 10 papers (the per-domain cap). Two domains returned fewer: Diabetes Epigenetics (8) and LADA New Research (3). Drug Repurposing returned only 5.

**Notable:** LADA and Drug Repurposing continue to show low publication volume, consistent with the gap analysis findings that these are under-researched areas.

### Key Therapy Mentions

No papers in the current 30-day window mentioned zimislecel, orforglipron, retatrutide, CagriSema, baricitinib, or teplizumab in their titles. This is based on title-only matching; these therapies may appear in abstracts/full text.

---

## Gap Analysis Summary

**Data freshness:** Gap data is from 2026-04-14 (2 days old); gap report from 2026-04-15. Both are current.

### Top 5 Under-Researched Intersections (from literature_gap_data.json)

| Rank | Domain 1 | Domain 2 | Gap Score | Joint Pubs |
|------|----------|----------|-----------|------------|
| 1 | Beta Cell Regen | Health Equity | 100.0 | 0 |
| 2 | Insulin Resistance | Islet Transplant | 100.0 | 1 |
| 3 | Islet Transplant | GWAS / Polygenic | 100.0 | 0 |
| 4 | Islet Transplant | Personalized Nutr | 100.0 | 0 |
| 5 | Islet Transplant | Drug Repurposing | 100.0 | 0 |

### Alignment with Tier 1 Contribution Areas

From the Research Doctrine, our Tier 1 areas are: Multi-Omics Biomarker Integration, Literature Synthesis & Gap Analysis, Clinical Trial Intelligence, Drug Repurposing, AI/ML Prediction, and Epidemiological Data Analysis.

**Direct alignment:**
- **Islet Transplant × Drug Repurposing** (Gap Score 100.0) — Directly maps to our Tier 1 Drug Repurposing focus. Existing immunosuppressants could be repurposed for islet protection; computational drug screening has not been applied here.
- **Drug Repurposing × Health Equity** (Gap Score 100.0, from gap report) — Drug repurposing could yield more affordable treatments for underserved populations.
- **Drug Repurposing × LADA** (Gap Score 100.0, from gap report) — LADA patients treated with suboptimal T2D drugs; systematic repurposing screens don't exist.
- **Health Equity × LADA** (Gap Score 100.0, from gap report) — LADA is massively underdiagnosed in minority populations; maps to our Tier 1 Epidemiological Data Analysis.

---

## Breaking News (Web Search — Last 7 Days)

### FDA Actions (Significant)

1. **Orforglipron (Foundayo) — FDA Approved April 1, 2026**
   Eli Lilly's oral GLP-1 receptor agonist approved for adults with obesity/overweight. This is the first oral small-molecule (non-peptide) GLP-1 RA — can be taken any time of day without food/water restrictions. This is a paradigm shift for GLP-1 therapy accessibility.
   *Relevance: Orforglipron is tracked in our trial database (NCT05929079 for retatrutide is related Lilly pipeline). The oral formulation has major implications for our Health Equity analysis — removes injection barrier.*
   *Validation level: BRONZE (single web source; awaiting peer-reviewed publication and regulatory filing details for GOLD)*

2. **Generic Dapagliflozin (Farxiga) — FDA Approved April 7, 2026**
   First generics approved for dapagliflozin tablets (5 mg and 10 mg), approved by multiple generic manufacturers including Biocon Pharma. Approved for reducing heart failure hospitalization risk in adults with T2D and CV disease/risk factors.
   *Relevance: SGLT2 inhibitor generics will dramatically increase access — directly relevant to our Health Equity monitoring.*

### Other Notable Developments

3. **MUSC Two-Part T1D Therapy (Breakthrough T1D Funded)**
   Medical University of South Carolina received $1M from Breakthrough T1D for a two-part therapy combining lab-made insulin-producing cells with custom-engineered protective immune cells — goal is immunosuppression-free beta cell restoration.
   *Relevance: Directly relevant to our Tier 3 monitoring of Stem Cell / Islet Biology and Immunology.*

4. **ADA Standards of Care 2026 Released**
   Key updates include recommending CGM at diabetes onset and removing prerequisites for insulin pump/AID initiation.
   *Relevance: Our Research Doctrine references alignment with ADA Standards of Care — all deliverables should be checked against the 2026 edition.*

---

## Recommended Actions

### Immediate (Today)

1. **Review cross-domain paper [41986815]** — "Multi-tissue multi-omics integration reveals tissue-specific pathways, gene networks and drug candidates." This hits two of our Tier 1 areas (Multi-Omics + Drug Repurposing). Retrieve the full abstract and assess for inclusion in our analysis pipeline.

2. **Update tracker with orforglipron FDA approval.** Foundayo (orforglipron) approved April 1, 2026 — this is a key therapy we track. Add to the Research Findings Summary and flag for the Clinical Trial Dashboard.

3. **Update tracker with generic dapagliflozin approval.** First SGLT2 inhibitor generic — implications for Health Equity analysis.

### This Week

4. **Review cross-domain paper [41985330]** — "Multi-strain probiotic enhances metformin tolerance via gut microbiome and bile acid pathways." Relevant to Microbiome-Metabolic Pathway Analysis (Tier 2).

5. **Verify ADA Standards of Care 2026 alignment.** The new ADA Standards have been released. Per the Research Doctrine QA Checklist, all deliverables should be reviewed for consistency with ADA Standards of Care 2026.

6. **Monitor Eli Lilly baricitinib Phase 3 trials** (NCT07222137, NCT07222332). These are newly recruiting Phase 3 trials for T1D prevention/preservation — high priority for our Clinical Trial Intelligence tracking.

### When Convenient

7. **Re-run gap analysis** — Results are 2 days old, which is acceptable, but consider refreshing weekly. Run: `python project1_literature_gap_analysis.py`

8. **Consider expanding PubMed keyword search** to capture key therapy names (orforglipron, retatrutide, CagriSema, baricitinib, teplizumab, zimislecel) in abstracts, not just titles. Current title-only matching returned 0 hits for all key therapies.

9. **452 stale files flagged** — Most are historical snapshots and paper library entries. No action needed unless specific files are failing to update.

---

*Generated by automated monitor task — 2026-04-16*
*Data integrity: All five key files present and read successfully. Snapshot comparison performed against 2026-04-15 data. Web search performed for breaking news.*
